Year: 2021
Type: review
Abstract: mutations that not only halt the normal function of p53, but also may acquire oncogenic gain of functions that favor tumorigenesis. Although considered undruggable for a long time, evidence has proven the capability of many compounds to restore a wild-type (wt)-like function to mutant p53 (mutp53). However, they have not reached the clinic to date. Structural studies have strongly contributed to the knowledge about p53 structure, stability, dynamics, function, and regulation. Importantly, they have afforded relevant insights into wt and mutp53 pharmacology at molecular levels, fostering the design and development of p53-targeted anticancer therapies. Herein, we provide an integrated view of mutp53 regulation, particularly focusing on mutp53 structural traits and on targeting agents capable of its reactivation, including their biological, biochemical and biophysical features. With this, we expect to pave the way for the development of improved small molecules that may advance precision cancer therapy by targeting p53.
Source: Cancers
Authors: Ana Sara Gomes(Conceptualization, Investigation, Writing – original draft, Writing – review & editing), Helena Ramos(Investigation, Writing – review & editing), Alberto Inga(Funding acquisition, Investigation, Writing – review & editing), Emília Sousa(Funding acquisition, Investigation, Writing – review & editing), Lucília Saraiva(Conceptualization, Funding acquisition, Investigation, Project administration, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,376
Funders: Associazione Italiana per la Ricerca sul Cancro, Ministério da Ciência, Tecnologia e Ensino Superior, Fondazione Italiana per la Ricerca sul Cancro, Centro Interdisciplinar de Investigação Marinha e Ambiental, Rede de Química e Tecnologia, Laboratório Associado para a Química Verde, Fundação para a Ciência e a Tecnologia
OpenAlex ID: W3180074961
